Use of PRAME immunostaining to distinguish early melanoma in situ from benign pigmented conditions
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
BACKGROUND: PRAME (PReferentially expressed Antigen in MElanoma) is an antigen that shows marked overexpression in melanoma compared to normal skin melanocytes. PRAME immunohistochemistry has proven effective in distinguishing melanocytic nevi from melanoma, but it is unclear if it may be used to distinguish melanoma in situ from other benign pigmented lesions. In particular, differentiating from melanocytic hyperplasia in sun-damaged skin is sometimes clinically and histopathologically challenging. We hypothesized that PRAME staining of solar lentigo, sun-damaged skin, and melanoma in situ would aid in setting a threshold of positivity that could be useful in evaluating such conditions.
METHODS: We collected and stained typical examples of solar lentigo, melanoma in situ, and non-lesional sun-damaged skin by PRAME immunohistochemistry to assess a potential cutoff of PRAME positivity.
RESULTS: Solar lentigo and non-lesional sun-damaged skin had 10 or fewer PRAME-positive cells per millimeter (mean 1.2), on the other hand melanoma in situ had at least 16 (mean 75.1).
CONCLUSIONS: PRAME immunostaining appears sensitive and specific in the current series. This could be clinically useful for distinguishing melanoma in situ from benign melanocytic hyperplasia in sun-damaged skin. However, further studies are required to determine if 10 cells per millimeter is an acceptable threshold of positivity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Journal of cutaneous pathology - 49(2022), 6 vom: 15. Juni, Seite 510-514 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Olds, Hailey [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigens, Neoplasm |
|---|
| Anmerkungen: |
Date Completed 20.05.2022 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cup.14212 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336789823 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336789823 | ||
| 003 | DE-627 | ||
| 005 | 20231227130714.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cup.14212 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM336789823 | ||
| 035 | |a (NLM)35146798 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Olds, Hailey |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of PRAME immunostaining to distinguish early melanoma in situ from benign pigmented conditions |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.05.2022 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: PRAME (PReferentially expressed Antigen in MElanoma) is an antigen that shows marked overexpression in melanoma compared to normal skin melanocytes. PRAME immunohistochemistry has proven effective in distinguishing melanocytic nevi from melanoma, but it is unclear if it may be used to distinguish melanoma in situ from other benign pigmented lesions. In particular, differentiating from melanocytic hyperplasia in sun-damaged skin is sometimes clinically and histopathologically challenging. We hypothesized that PRAME staining of solar lentigo, sun-damaged skin, and melanoma in situ would aid in setting a threshold of positivity that could be useful in evaluating such conditions | ||
| 520 | |a METHODS: We collected and stained typical examples of solar lentigo, melanoma in situ, and non-lesional sun-damaged skin by PRAME immunohistochemistry to assess a potential cutoff of PRAME positivity | ||
| 520 | |a RESULTS: Solar lentigo and non-lesional sun-damaged skin had 10 or fewer PRAME-positive cells per millimeter (mean 1.2), on the other hand melanoma in situ had at least 16 (mean 75.1) | ||
| 520 | |a CONCLUSIONS: PRAME immunostaining appears sensitive and specific in the current series. This could be clinically useful for distinguishing melanoma in situ from benign melanocytic hyperplasia in sun-damaged skin. However, further studies are required to determine if 10 cells per millimeter is an acceptable threshold of positivity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PRAME | |
| 650 | 4 | |a immunohistochemistry | |
| 650 | 4 | |a melanoma in situ | |
| 650 | 4 | |a solar lentigo | |
| 650 | 7 | |a Antigens, Neoplasm |2 NLM | |
| 650 | 7 | |a PRAME protein, human |2 NLM | |
| 700 | 1 | |a Utz, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Abrams, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Terrano, David |e verfasserin |4 aut | |
| 700 | 1 | |a Mehregan, Darius |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cutaneous pathology |d 1974 |g 49(2022), 6 vom: 15. Juni, Seite 510-514 |w (DE-627)NLM000403180 |x 1600-0560 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2022 |g number:6 |g day:15 |g month:06 |g pages:510-514 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cup.14212 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2022 |e 6 |b 15 |c 06 |h 510-514 | ||